LIFECORE BIOMEDICAL, INC. Increase (Decrease) in Restricted Cash
LIFECORE BIOMEDICAL, INC. (LFCR) reported Increase (Decrease) in Restricted Cash of $100.00 thousand for the 12-month period ending 2017-05-28, per its 10-K filed 2018-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-08-09
- LIFECORE BIOMEDICAL, INC. increase (decrease) in restricted cash for fiscal 2017 was $100.00K, a 55.56% decline from fiscal 2016.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in restricted cash for fiscal 2016 was $225.00K.
| Period end | Increase (Decrease) in Restricted Cash 12 month |
|---|---|
| 2017-05-28 | $100.00K 10-K · filed 2018-08-09 |
| 2016-05-29 | $225.00K 10-K · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |